In Vitro Bioactivity of a Recombinant Human Collagen Peptide in a Filler Biomimetic Skin Model
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Chunyan He und 4 weiteren Autor:innen. Beteiligte Einrichtung: L'Oreal Research and Innovation, Shanghai, China. Hauptthemen laut MEDLINE: Dermal Fillers, Collagen, Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: L'Oreal Research & Innovation Group.
Abstract (Originalsprache)
Background
Recombinant human collagen peptides (rhCol peptides) have demonstrated considerable promise in various biomedical applications, including wound healing, dermatological treatments, aesthetic procedures, cosmetic formulations, and personal healthcare. Recently, their incorporation as a bioactive component in dermal filler products has gained significant attraction within the aesthetic and cosmetic fields.
Aims
To elucidate the beneficial bio‐efficacy of rhCol peptides as a dermal filler, underlying mechanisms from both the cell and tissue levels were explored.
Methods
The stimulatory effect of rhCol peptides on extracellular matrix (ECM) production was confirmed in 2D human fibroblast cultures at mRNA levels. Subsequently, its impact on skin rejuvenation was illustrated, utilizing a novel, in‐house developed 3D in vitro filler biomimetic skin model, tissue morphology, epidermal proliferation and differentiation, as well as dermal ECM deposition were investigated. Transcriptomic analysis further offered an in‐depth view of molecular pathways underlying the phenotypical change observed at cellular and tissue levels.
Results
In the 2D cell model, matrix remodeling–related genes such as Collagen type I and III, Elastin, Fibrillin 1, Hyaluronic acid synthases 1, 2, and 3 were significantly upregulated upon treatment with rhCol III peptides. Its direct binding to the dermal scaffold was confirmed within a novel filler biomimetic in vitro skin model, providing compelling evidence of their beneficial effects on both epidermal and dermal compartments, embodied in improved epidermis regeneration (Ki67, COL17A1) and dermis remodeling (FBN1 and glycosaminoglycans). Furthermore, transcriptomic analysis provided valuable insights into the potential mechanisms of downregulated inflammation, senescence and apoptosis; upregulated integrin binding; and extracellular matrix formation resulted from the binding of rhCol III peptides to the dermal scaffold.
Conclusions
These findings collectively support the pro‐ECM potential of such rhCol III peptides as a promising biomaterial for dermal filler, as well as potential cosmetic applications. Limited by the gap between in vitro mimetic model and real injection, further clinical trials should be taken to reconfirm the potential benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- L'Oreal Research and Innovation, Shanghai, China.
ORCID-Profile: Chunyan He, Qiao Zhang, Nan Huang
Förderung
- L'Oreal Research & Innovation Group
Zitieren
APA
He, C., Wang, R., Zhang, Q., Wang, Y., & Huang, N. (2025). In Vitro Bioactivity of a Recombinant Human Collagen Peptide in a Filler Biomimetic Skin Model. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70592
Vancouver
He C, Wang R, Zhang Q, Wang Y, Huang N. In Vitro Bioactivity of a Recombinant Human Collagen Peptide in a Filler Biomimetic Skin Model. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70592
BibTeX
@article{He2025,
author = {He, Chunyan and Wang, Ranran and Zhang, Qiao and Wang, Yehong and Huang, Nan},
title = {In Vitro Bioactivity of a Recombinant Human Collagen Peptide in a Filler Biomimetic Skin Model},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70592}
}
EUVIMED